Prevention and treatment of cerebral amyloid angiopathy

Abstract

The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 12 / 181,238 filed on Jul. 28, 2008, which is a continuation-in-part of U.S. application Ser. No. 12 / 106,206 filed Apr. 18, 2008, which claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Ser. No. 60 / 925,228, filed Apr. 18, 2007, each of which is incorporated herein by reference in its entirety for all purposes.REFERENCE TO A “SEQUENCE LISTING” A TABLE, OR A COMPUTER PROGRAM LISTING[0002]The Sequence Listing written in file SEQLIST15270C000320US.txt is 45,052 bytes, and was created on Sep. 18, 2008, for application Ser. No. 12 / 181,238, Schroeter et al, entitled “PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY”. The information contained in this file is hereby incorporated by reference.BACKGROUND OF THE INVENTION[0003]Over expression of mutant human amyloid precursor protein (APP) in various transgenic mice leads to several Alzheimer's disease (...

AI Technical Summary

Benefits of technology

[0019]The invention provides methods of treating Alzheimer's disease that comprise administering an antibody that is specific for the N-terminus of Aβ at a dose that reduces or inhibits development of vascular amyloidogenic pathology, minimizes microhemorrhage, and or reduces or inhibits development of neuritic pathology. Optionally, in some methods the antibody binds within residues 1-5 of Aβ. Optionally, the antibody is a humanized, human, or chimeric antibody. Optionally, the humanized antibody is 3D6. Optionally, the 3D6 humanized antibody is bapineuzumab. Optionally, the humanized antibody is 12A11.

[0020]The invention provides methods for treating Alzheimer's disease that comprise administering an antibody that is specific for the N-terminus of Aβ at a dose that reduces or inhibits vascular amyloidogenic pathology, minimizes microhemorrhage, and or improves patient's cognitive function. Optionally, in some methods the antibody binds within residues 1-5 of Aβ. Optionally, the antibody is a humanized, human, or chimeric antibody. Optionally, the humanized antibody is 3D6. Optionally, the 3D6 humanized antibody is bapineuzumab. Optionally, the humanized antibody is 12A11.

Problems solved by technology

However, predictive clinical implications remain unclear, especially in light of favorable behavioral outcomes in some of these same studies (see D. M. Wilcock et al, supra), the lack of ultrastructural differences in vascular morphology of hemosiderin-positive vessels in untreated and treated transgenic mice (see G. J. Burbach et al., Neurobiol Aging 28, 202-12 (2007)) and, notably, the lack of evidence for significant bleeding or stroke-related consequences in ongoing clinical trials.

In addition, little is known about the degree to which VAβ is ultimately affected by Aβ immunotherapeutic approaches; for example, whether outcome measures in chronic treatment paradigms might differ from more acute studies.

Images